EyePoint Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US30233G2093

SecurityEYPT / EyePoint Pharmaceuticals, Inc.
InsiderZaderej Karen L.
This page shows the track record and history of Zaderej Karen L. insider trades in EyePoint Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Zaderej Karen L. in EYPT / EyePoint Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-05-19 5,000 5.9900 5,000 5.9900 29,950 113 14.1900 41,000 136.89
2025-05-16 5,000 5.8100 5,000 5.8100 29,050
2025-05-15 5,000 5.4700 5,000 5.4700 27,350
2025-05-14 5,000 5.4200 5,000 5.4200 27,100
2024-08-19 12,500 7.9800 12,500 7.9800 99,750

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EYPT / EyePoint Pharmaceuticals, Inc. Insider Trades
Insider Sales - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Zaderej Karen L. in EYPT / EyePoint Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EYPT / EyePoint Pharmaceuticals, Inc. Insider Trades
Insider Transaction History
File
Date
Trade
Date
Form Insider Ticker Security Title Code 10b5-1 Direct Exercise
Price
Unit
Price
Units
Changed
Value
Changed (1K)
Remaining
Options
Remaining
Shares
2025-07-11 2025-07-11 4 Zaderej Karen L. EYPT Common Stock M - Exercise D 2,000 38,500
2025-05-19 2025-05-19 4 Zaderej Karen L. EYPT Common Stock P - Purchase D 5.9900 5,000 30 36,500
2025-05-19 2025-05-16 4 Zaderej Karen L. EYPT Common Stock P - Purchase D 5.8100 5,000 29 31,500
2025-05-15 2025-05-15 4 Zaderej Karen L. EYPT Common Stock P - Purchase D 5.4700 5,000 27 26,500
2025-05-15 2025-05-14 4 Zaderej Karen L. EYPT Common Stock P - Purchase D 5.4200 5,000 27 21,500
2024-08-21 2024-08-19 4 Zaderej Karen L. EYPT Common Stock P - Purchase D 7.9800 12,500 100 16,500
2024-07-12 2024-07-11 4 Zaderej Karen L. EYPT Common Stock M - Exercise D 2,000 4,000
2023-07-12 2023-07-11 4 Zaderej Karen L. EYPT Common Stock M - Exercise D 2,000 2,000
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)